Sanofi

It's

already illegal for Sanofi, Eli Lilly, and Novo Nordisk to say, hey, look, guys, we're going to charge them this big old price.

And if they don't have it, So what? That's their problem.

Go find it.

I can be very quick on this one.

I'm just going to bring up what Sanofi said, which was, I think, the most detailed comment when it comes to China.

And the CEO said that China, described China as a thriving hub for scientific advancement and said Sanofi plans to source innovation globally, including China, which of course is what every pharma company continues to say.

And I think she also noted that Sanofi's strong commercial presence in the region also I think helps them in terms of both manufacturing and bringing in partnerships in drug development.

So the head of R&D then also Paolo said, here we go, faster translational efficiency as a key advantage of working with Chinese partners.

Now, I don't think there's anything new in any of this, but I would say that it's quite nice that Verifarma company specifically brings it out and says it because we pontificate a lot about what is positive about China.

And the World Health Organization had just announced that snake venom envenomation was a neglected tropical disease.

And the reason they did that was that Sanofi had just pulled out one of their key antivenoms for Africa, where they had chosen to discontinue it in 2014. they had not really updated the world until 2016 but they'd stopped producing it and so because there was no communication they were stuck with a gap where suddenly a lot of areas had no antivenom no no medical recourse and the nature of the field as you'd mentioned There's 650 species of snake around the world that are of medical concern.

There are about 35 different products that either treat a single snake or a couple snakes in a certain region.

And those products are made from horse serum or sheep serum.

And so it becomes neglected.

It's also neglected because if you unified it, it's about a $500 million a year market, but it's split.

It's fractured across 35 products, and that makes it very economically difficult undesirable which is why Sanofi pulled out they're like why the hell are we making this we're not making any money on it right so that's that's the field Sanofi and World Health Organization tries to shine some light on it I was reading about it and I'm I'm just interested in developing world because I grew up in a I grew up in a Zutul village and we're about four hours away from the proper hospital and so I'm kind of familiar with the kind of the the I had very bad asthma when I was a kid, so I was familiar with the unique needs and like deficits of not having hospitals nearby and how you kind of make ends meet and how for a lot of the world, for actually, I would say a large proportion of the human experience is that what you have nearby is not a hospital.

You have a pharmacy, which is really just a store in the front of someone like a shop that has some shelves of some medicines that don't require cold chain.